Table 3

Clinical trials of clear cell carcinoma using molecular targeted therapy

Study identifier
GOG-0268CompletedNewly diagnosed stage III or IV OCCCTemsirolimus,
carboplatin, and paclitaxel
GOG-0254CompletedPersistent or recurrent OCCCSunitinibIIPDGFRs and VEGFRsNCT00979992
ENMD-2076-OCCCompletedPersistent or recurrent OCCCENMD-2076IIAURKA, VEGFRs, FGFRs,
Flt3, and c-kit
NRG-GY001CompletedPersistent or recurrent OCCCCabozantinibIIMET, RET, VEGFR2, and AXLNCT02315430
GOG-0283Active, not recruitingPersisent or recurrent OCCC or endometrial CCCDasatinibIIbcr-abl, c-kit, and PDGFNCT02059265
NiCCCRecruitingPersistent or recurrent OCCC and endometrial CCCNintendanibIIFGFRs, PDGFRs, and VEGFRsNCT02866370
MOCCARecruitingPersistent or recurrent OCCCDurvalumabIIPD-L1NCT03405454
BrUOG 354RecruitingPersistent or recurrent OCCC or extra-renal origin CCCNivolumab ± ipilimumabIIPD-1, CTLA4NCT03355976
NRG-GY016SuspendedPersistent or recurrent OCCCPembrolozimab and epacadostatIIPD-1 and IDO1NCT03602586
  • AURKA, aurora kinase A; CCC, clear cell carcinoma; CTLA4, cytotoxic T-lymphocyte-associated protein 4; FGFR, fibroblast growth factor receptor; Flt3, FMS-like tyrosine kinase; IDO1, idoleamine 2,3-dioxygenase-1; MET, MET proto-oncogene, receptor tyrosine kinase; mTOR, mammalian target of rapamycin; OCCC, ovarian clear cell carcinoma; PD-1, programmed cell death 1; PDGF, platelet-derived growth factor; PDGFR, platelet-derived growth factor receptor; PD-L1, programmed cell death 1 ligand; RET, RET proto-oncogene, receptor tyrosine kinase; VEGFR, vascular endothelial growth factor receptor.